Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Residence Characteristics | 19 | 2020 | 190 | 5.340 |
Why?
|
Marijuana Smoking | 16 | 2020 | 39 | 4.840 |
Why?
|
Alcohol Drinking | 25 | 2022 | 257 | 3.770 |
Why?
|
Urban Population | 12 | 2019 | 87 | 3.770 |
Why?
|
African Americans | 16 | 2022 | 1443 | 3.340 |
Why?
|
Adolescent | 74 | 2022 | 3571 | 2.490 |
Why?
|
Adolescent Behavior | 12 | 2020 | 61 | 2.360 |
Why?
|
Young Adult | 55 | 2022 | 2626 | 2.170 |
Why?
|
Risk-Taking | 9 | 2019 | 97 | 2.050 |
Why?
|
Emigrants and Immigrants | 7 | 2020 | 250 | 1.900 |
Why?
|
Students | 18 | 2018 | 175 | 1.720 |
Why?
|
Smoking | 17 | 2022 | 493 | 1.590 |
Why?
|
Male | 106 | 2022 | 19488 | 1.580 |
Why?
|
Female | 111 | 2022 | 20126 | 1.560 |
Why?
|
Humans | 131 | 2022 | 32297 | 1.400 |
Why?
|
Poverty | 8 | 2019 | 111 | 1.380 |
Why?
|
Marijuana Abuse | 6 | 2019 | 18 | 1.360 |
Why?
|
Cannabis | 5 | 2022 | 20 | 1.360 |
Why?
|
Universities | 19 | 2018 | 150 | 1.330 |
Why?
|
HIV Infections | 6 | 2021 | 388 | 1.250 |
Why?
|
Social Environment | 6 | 2019 | 80 | 1.240 |
Why?
|
Hispanic Americans | 10 | 2019 | 949 | 1.230 |
Why?
|
Longitudinal Studies | 23 | 2019 | 786 | 1.210 |
Why?
|
Alcohol-Related Disorders | 5 | 2021 | 22 | 1.190 |
Why?
|
Alcoholism | 6 | 2021 | 102 | 1.150 |
Why?
|
Adult | 60 | 2022 | 9467 | 1.140 |
Why?
|
Alcoholic Intoxication | 5 | 2014 | 32 | 1.120 |
Why?
|
Diabetes Mellitus, Type 1 | 8 | 2022 | 244 | 1.080 |
Why?
|
Tobacco Use Disorder | 4 | 2021 | 84 | 1.020 |
Why?
|
Child | 27 | 2022 | 2472 | 0.930 |
Why?
|
United States | 30 | 2022 | 3983 | 0.890 |
Why?
|
Opioid-Related Disorders | 2 | 2022 | 56 | 0.890 |
Why?
|
Baltimore | 9 | 2020 | 51 | 0.830 |
Why?
|
Logistic Models | 15 | 2019 | 788 | 0.790 |
Why?
|
Substance-Related Disorders | 6 | 2018 | 124 | 0.790 |
Why?
|
Risk Factors | 27 | 2022 | 3876 | 0.780 |
Why?
|
Mood Disorders | 4 | 2018 | 20 | 0.770 |
Why?
|
Product Labeling | 4 | 2021 | 13 | 0.730 |
Why?
|
Cluster Analysis | 6 | 2016 | 131 | 0.720 |
Why?
|
Minority Groups | 3 | 2019 | 76 | 0.710 |
Why?
|
Social Support | 4 | 2019 | 180 | 0.710 |
Why?
|
Preventive Health Services | 1 | 2020 | 44 | 0.710 |
Why?
|
Mental Disorders | 6 | 2014 | 119 | 0.710 |
Why?
|
Multifactorial Inheritance | 2 | 2020 | 21 | 0.700 |
Why?
|
Cross-Sectional Studies | 20 | 2020 | 1522 | 0.700 |
Why?
|
North Carolina | 29 | 2020 | 1520 | 0.680 |
Why?
|
Social Problems | 1 | 2019 | 2 | 0.680 |
Why?
|
Cocaine | 4 | 2012 | 270 | 0.650 |
Why?
|
Depression | 6 | 2016 | 436 | 0.630 |
Why?
|
European Continental Ancestry Group | 4 | 2018 | 1180 | 0.630 |
Why?
|
Peer Group | 5 | 2020 | 44 | 0.570 |
Why?
|
Cohort Studies | 9 | 2021 | 1832 | 0.560 |
Why?
|
Mothers | 4 | 2018 | 87 | 0.560 |
Why?
|
Homosexuality, Male | 3 | 2019 | 83 | 0.560 |
Why?
|
Mammography | 6 | 2006 | 41 | 0.550 |
Why?
|
Social Behavior | 4 | 2019 | 65 | 0.520 |
Why?
|
Age Factors | 10 | 2016 | 1204 | 0.520 |
Why?
|
Postmenopause | 7 | 2006 | 409 | 0.520 |
Why?
|
Mass Screening | 4 | 2019 | 263 | 0.520 |
Why?
|
Commerce | 4 | 2020 | 43 | 0.480 |
Why?
|
Breast | 5 | 2005 | 61 | 0.470 |
Why?
|
Estrogen Replacement Therapy | 9 | 2006 | 188 | 0.460 |
Why?
|
Models, Statistical | 6 | 2015 | 176 | 0.440 |
Why?
|
Sexually Transmitted Diseases | 2 | 2015 | 42 | 0.430 |
Why?
|
Receptors, Dopamine | 1 | 2012 | 20 | 0.410 |
Why?
|
Social Dominance | 1 | 2012 | 18 | 0.410 |
Why?
|
Putamen | 1 | 2012 | 25 | 0.410 |
Why?
|
Caudate Nucleus | 1 | 2012 | 25 | 0.410 |
Why?
|
Socioeconomic Factors | 7 | 2019 | 422 | 0.400 |
Why?
|
Program Development | 1 | 2012 | 97 | 0.400 |
Why?
|
Prevalence | 11 | 2019 | 986 | 0.400 |
Why?
|
Comorbidity | 8 | 2019 | 572 | 0.390 |
Why?
|
Censuses | 1 | 2011 | 10 | 0.390 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 2012 | 97 | 0.390 |
Why?
|
Educational Status | 6 | 2018 | 177 | 0.380 |
Why?
|
Tobacco | 3 | 2021 | 57 | 0.370 |
Why?
|
Suicide, Attempted | 7 | 2009 | 32 | 0.370 |
Why?
|
Blood Glucose | 4 | 2022 | 496 | 0.350 |
Why?
|
Sexual Behavior | 5 | 2019 | 106 | 0.350 |
Why?
|
Virginia | 11 | 2018 | 66 | 0.340 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2019 | 353 | 0.340 |
Why?
|
Middle Aged | 27 | 2020 | 11949 | 0.330 |
Why?
|
Sex Factors | 5 | 2016 | 674 | 0.330 |
Why?
|
Diabetes Complications | 3 | 2019 | 180 | 0.330 |
Why?
|
Gonadal Steroid Hormones | 2 | 2006 | 29 | 0.330 |
Why?
|
Insulin | 3 | 2022 | 368 | 0.320 |
Why?
|
Violence | 2 | 2019 | 15 | 0.310 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 560 | 0.290 |
Why?
|
Crime | 2 | 2019 | 5 | 0.290 |
Why?
|
Sex Hormone-Binding Globulin | 2 | 2006 | 14 | 0.280 |
Why?
|
Depressive Disorder | 4 | 2017 | 76 | 0.280 |
Why?
|
Minors | 1 | 2005 | 2 | 0.270 |
Why?
|
Odds Ratio | 4 | 2021 | 480 | 0.270 |
Why?
|
Stress, Psychological | 2 | 2018 | 218 | 0.270 |
Why?
|
Marketing | 2 | 2018 | 24 | 0.270 |
Why?
|
Estrogens, Conjugated (USP) | 6 | 2006 | 128 | 0.270 |
Why?
|
Staphylococcal Infections | 5 | 2007 | 63 | 0.270 |
Why?
|
Medroxyprogesterone Acetate | 7 | 2006 | 93 | 0.270 |
Why?
|
Staphylococcus aureus | 4 | 2007 | 46 | 0.260 |
Why?
|
Legislation, Drug | 2 | 2019 | 8 | 0.260 |
Why?
|
Cocaine-Related Disorders | 2 | 2007 | 105 | 0.260 |
Why?
|
African Continental Ancestry Group | 1 | 2007 | 364 | 0.260 |
Why?
|
Models, Theoretical | 1 | 2006 | 138 | 0.260 |
Why?
|
Unsafe Sex | 2 | 2017 | 24 | 0.260 |
Why?
|
Focus Groups | 3 | 2021 | 111 | 0.250 |
Why?
|
Health Promotion | 3 | 2017 | 242 | 0.250 |
Why?
|
Parents | 2 | 2019 | 150 | 0.240 |
Why?
|
Age of Onset | 3 | 2018 | 100 | 0.240 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 3 | 2012 | 36 | 0.240 |
Why?
|
Mental Health Services | 2 | 2003 | 28 | 0.240 |
Why?
|
Carrier State | 5 | 2007 | 21 | 0.230 |
Why?
|
Health Surveys | 4 | 2019 | 202 | 0.230 |
Why?
|
Progestins | 2 | 2006 | 21 | 0.230 |
Why?
|
Self Concept | 2 | 2013 | 42 | 0.220 |
Why?
|
Prospective Studies | 10 | 2018 | 2274 | 0.220 |
Why?
|
Air Microbiology | 4 | 2007 | 18 | 0.210 |
Why?
|
Dyslexia | 3 | 2007 | 8 | 0.210 |
Why?
|
Hallucinogens | 1 | 2022 | 12 | 0.210 |
Why?
|
Models, Psychological | 2 | 2005 | 24 | 0.210 |
Why?
|
Factor Analysis, Statistical | 4 | 2019 | 75 | 0.210 |
Why?
|
Diabetic Ketoacidosis | 2 | 2019 | 10 | 0.210 |
Why?
|
Sexual Partners | 2 | 2019 | 35 | 0.200 |
Why?
|
Data Interpretation, Statistical | 4 | 2007 | 110 | 0.190 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 262 | 0.190 |
Why?
|
Anti-HIV Agents | 1 | 2021 | 54 | 0.190 |
Why?
|
Alcoholic Beverages | 1 | 2020 | 6 | 0.190 |
Why?
|
Biometry | 2 | 2000 | 14 | 0.190 |
Why?
|
Employment | 3 | 2016 | 49 | 0.190 |
Why?
|
Managed Care Programs | 1 | 2000 | 41 | 0.180 |
Why?
|
Geography | 2 | 2011 | 35 | 0.180 |
Why?
|
Parent-Child Relations | 2 | 2016 | 46 | 0.180 |
Why?
|
Heroin | 1 | 2020 | 23 | 0.180 |
Why?
|
Progesterone | 4 | 2005 | 95 | 0.180 |
Why?
|
Data Collection | 5 | 2013 | 185 | 0.180 |
Why?
|
Infant Behavior | 2 | 2016 | 9 | 0.180 |
Why?
|
Health Status | 2 | 2020 | 402 | 0.170 |
Why?
|
Common Cold | 4 | 2007 | 11 | 0.170 |
Why?
|
Public Health | 1 | 2020 | 83 | 0.170 |
Why?
|
Motivation | 1 | 2020 | 114 | 0.170 |
Why?
|
Academic Medical Centers | 1 | 2000 | 160 | 0.170 |
Why?
|
Sex Education | 1 | 2019 | 3 | 0.170 |
Why?
|
Law Enforcement | 2 | 2020 | 27 | 0.170 |
Why?
|
Perception | 1 | 2019 | 98 | 0.160 |
Why?
|
Interviews as Topic | 3 | 2015 | 263 | 0.160 |
Why?
|
Product Packaging | 1 | 2018 | 3 | 0.160 |
Why?
|
Adipose Tissue | 1 | 2022 | 345 | 0.160 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 134 | 0.160 |
Why?
|
Community-Based Participatory Research | 3 | 2017 | 113 | 0.160 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2018 | 19 | 0.160 |
Why?
|
Women, Working | 1 | 2018 | 12 | 0.160 |
Why?
|
Ethnic Groups | 3 | 2019 | 480 | 0.160 |
Why?
|
Registries | 1 | 2019 | 300 | 0.160 |
Why?
|
Breast Feeding | 1 | 2018 | 43 | 0.160 |
Why?
|
Nasal Mucosa | 4 | 2006 | 19 | 0.150 |
Why?
|
Quality of Life | 6 | 2019 | 915 | 0.150 |
Why?
|
Body Weight | 1 | 2019 | 311 | 0.150 |
Why?
|
Psychometrics | 3 | 2016 | 137 | 0.150 |
Why?
|
Health Services Accessibility | 2 | 2014 | 242 | 0.150 |
Why?
|
Self Efficacy | 2 | 2018 | 78 | 0.150 |
Why?
|
Follow-Up Studies | 11 | 2019 | 2296 | 0.150 |
Why?
|
Smoking Cessation | 3 | 2015 | 195 | 0.150 |
Why?
|
Condoms | 1 | 2017 | 35 | 0.140 |
Why?
|
Genotype | 1 | 2019 | 742 | 0.140 |
Why?
|
Adiposity | 1 | 2018 | 197 | 0.140 |
Why?
|
Social Facilitation | 2 | 2007 | 2 | 0.140 |
Why?
|
Urban Health | 1 | 2016 | 14 | 0.140 |
Why?
|
Tobacco, Smokeless | 1 | 2015 | 13 | 0.130 |
Why?
|
Sexuality | 1 | 2015 | 9 | 0.130 |
Why?
|
Cognition Disorders | 1 | 1998 | 383 | 0.130 |
Why?
|
Student Health Services | 1 | 2014 | 9 | 0.120 |
Why?
|
Health Education | 1 | 2016 | 157 | 0.120 |
Why?
|
Health Services | 1 | 2015 | 39 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2012 | 675 | 0.120 |
Why?
|
Bone Density | 2 | 2006 | 186 | 0.120 |
Why?
|
Hospitalization | 6 | 2006 | 465 | 0.120 |
Why?
|
Counseling | 1 | 2014 | 99 | 0.120 |
Why?
|
Life Change Events | 2 | 2021 | 21 | 0.120 |
Why?
|
Aggression | 2 | 2019 | 30 | 0.120 |
Why?
|
Rural Population | 2 | 2014 | 274 | 0.120 |
Why?
|
Health Personnel | 1 | 2015 | 121 | 0.110 |
Why?
|
Regression Analysis | 2 | 2006 | 296 | 0.110 |
Why?
|
Self Administration | 2 | 2012 | 303 | 0.110 |
Why?
|
Child Abuse | 1 | 2013 | 30 | 0.110 |
Why?
|
Friends | 1 | 2012 | 8 | 0.110 |
Why?
|
Automobile Driving | 1 | 2012 | 24 | 0.110 |
Why?
|
Analysis of Variance | 2 | 2012 | 470 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 171 | 0.110 |
Why?
|
Homovanillic Acid | 1 | 2012 | 11 | 0.110 |
Why?
|
Drug Prescriptions | 1 | 2012 | 54 | 0.100 |
Why?
|
Menstrual Cycle | 1 | 2012 | 59 | 0.100 |
Why?
|
Central Nervous System Stimulants | 1 | 2012 | 75 | 0.100 |
Why?
|
Community Health Services | 1 | 2012 | 55 | 0.100 |
Why?
|
Inflammation | 2 | 2006 | 542 | 0.100 |
Why?
|
Restaurants | 1 | 2011 | 7 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2012 | 82 | 0.100 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 124 | 0.100 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 190 | 0.090 |
Why?
|
Macaca fascicularis | 1 | 2012 | 401 | 0.090 |
Why?
|
C-Reactive Protein | 3 | 2006 | 238 | 0.090 |
Why?
|
Central Nervous System Depressants | 1 | 2011 | 63 | 0.090 |
Why?
|
Pilot Projects | 1 | 2012 | 536 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 1428 | 0.090 |
Why?
|
Electroconvulsive Therapy | 2 | 2001 | 27 | 0.090 |
Why?
|
Depressive Disorder, Major | 2 | 2001 | 42 | 0.090 |
Why?
|
Aged | 13 | 2019 | 10398 | 0.090 |
Why?
|
Protective Clothing | 2 | 2007 | 26 | 0.090 |
Why?
|
Statistics as Topic | 3 | 2006 | 110 | 0.090 |
Why?
|
Aging | 4 | 2002 | 953 | 0.090 |
Why?
|
Psychiatric Status Rating Scales | 3 | 2005 | 99 | 0.090 |
Why?
|
Attention | 2 | 2021 | 83 | 0.090 |
Why?
|
Population | 1 | 2009 | 8 | 0.090 |
Why?
|
Databases, Factual | 1 | 2011 | 355 | 0.090 |
Why?
|
Anxiety Disorders | 2 | 2007 | 77 | 0.080 |
Why?
|
Matrix Metalloproteinase 9 | 2 | 2006 | 31 | 0.080 |
Why?
|
Family Characteristics | 1 | 2009 | 33 | 0.080 |
Why?
|
Family | 1 | 2009 | 115 | 0.080 |
Why?
|
Breast Neoplasms | 3 | 2005 | 759 | 0.080 |
Why?
|
Child Development | 1 | 2009 | 42 | 0.080 |
Why?
|
Ethanol | 1 | 2011 | 187 | 0.080 |
Why?
|
Rhinovirus | 2 | 2005 | 9 | 0.080 |
Why?
|
Estrone | 2 | 2006 | 7 | 0.080 |
Why?
|
Double-Blind Method | 5 | 2005 | 550 | 0.080 |
Why?
|
Reproducibility of Results | 5 | 2016 | 779 | 0.080 |
Why?
|
Child, Preschool | 3 | 2019 | 1281 | 0.080 |
Why?
|
Time Factors | 5 | 2018 | 2181 | 0.080 |
Why?
|
Sample Size | 1 | 2007 | 39 | 0.080 |
Why?
|
Internet | 3 | 2015 | 203 | 0.070 |
Why?
|
Psychosocial Deprivation | 1 | 2007 | 4 | 0.070 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2007 | 3 | 0.070 |
Why?
|
Social Identification | 1 | 2007 | 9 | 0.070 |
Why?
|
Research Design | 2 | 2007 | 313 | 0.070 |
Why?
|
Fluorenes | 1 | 2007 | 4 | 0.070 |
Why?
|
Likelihood Functions | 2 | 2014 | 48 | 0.070 |
Why?
|
Parenting | 1 | 2007 | 23 | 0.070 |
Why?
|
Discrimination Learning | 1 | 2007 | 19 | 0.070 |
Why?
|
Dopamine Agonists | 1 | 2007 | 28 | 0.070 |
Why?
|
Dopamine Antagonists | 1 | 2007 | 22 | 0.070 |
Why?
|
Phobic Disorders | 1 | 2007 | 9 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2006 | 511 | 0.070 |
Why?
|
Student Dropouts | 1 | 2006 | 5 | 0.070 |
Why?
|
Monte Carlo Method | 1 | 2006 | 19 | 0.070 |
Why?
|
Schizophrenia | 1 | 2007 | 31 | 0.070 |
Why?
|
Reinforcement Schedule | 1 | 2007 | 58 | 0.070 |
Why?
|
Medically Underserved Area | 1 | 2006 | 23 | 0.070 |
Why?
|
Piperazines | 1 | 2007 | 60 | 0.070 |
Why?
|
Receptors, Dopamine D3 | 1 | 2007 | 33 | 0.070 |
Why?
|
Vulnerable Populations | 1 | 2006 | 34 | 0.070 |
Why?
|
Animals | 5 | 2012 | 7694 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2006 | 17 | 0.070 |
Why?
|
Problem-Based Learning | 1 | 2006 | 29 | 0.070 |
Why?
|
Conditioning, Operant | 1 | 2007 | 92 | 0.070 |
Why?
|
Crack Cocaine | 1 | 2006 | 4 | 0.070 |
Why?
|
Schools | 1 | 2006 | 65 | 0.070 |
Why?
|
Education, Medical | 1 | 2006 | 70 | 0.070 |
Why?
|
Sampling Studies | 1 | 2005 | 43 | 0.070 |
Why?
|
Forecasting | 3 | 2020 | 145 | 0.070 |
Why?
|
Estradiol Congeners | 1 | 2005 | 2 | 0.070 |
Why?
|
Culture | 1 | 2005 | 41 | 0.070 |
Why?
|
Severity of Illness Index | 6 | 2007 | 926 | 0.070 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2007 | 120 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2005 | 47 | 0.060 |
Why?
|
Testosterone | 1 | 2005 | 54 | 0.060 |
Why?
|
Child Behavior Disorders | 1 | 2005 | 11 | 0.060 |
Why?
|
Anxiety | 1 | 2006 | 185 | 0.060 |
Why?
|
Behavior, Animal | 1 | 2007 | 262 | 0.060 |
Why?
|
Air Pollutants | 1 | 2005 | 21 | 0.060 |
Why?
|
Cough | 2 | 2020 | 20 | 0.060 |
Why?
|
Patient Dropouts | 2 | 2002 | 28 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2006 | 182 | 0.060 |
Why?
|
Students, Medical | 1 | 2006 | 131 | 0.060 |
Why?
|
Mexico | 2 | 2015 | 69 | 0.060 |
Why?
|
Picornaviridae Infections | 1 | 2004 | 4 | 0.060 |
Why?
|
Utilization Review | 2 | 2003 | 17 | 0.060 |
Why?
|
Staphylococcus | 1 | 2004 | 6 | 0.060 |
Why?
|
Child Behavior | 1 | 2004 | 27 | 0.060 |
Why?
|
Endothelium, Vascular | 1 | 2005 | 154 | 0.060 |
Why?
|
Religion | 2 | 2014 | 32 | 0.060 |
Why?
|
Cross Infection | 1 | 2004 | 48 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2019 | 4050 | 0.050 |
Why?
|
Interpersonal Relations | 2 | 2019 | 56 | 0.050 |
Why?
|
Adolescent Health Services | 1 | 2003 | 12 | 0.050 |
Why?
|
Infant | 2 | 2016 | 1076 | 0.050 |
Why?
|
Aftercare | 1 | 2003 | 31 | 0.050 |
Why?
|
Activities of Daily Living | 2 | 2001 | 258 | 0.050 |
Why?
|
Headache | 2 | 2020 | 78 | 0.050 |
Why?
|
Estrogens | 2 | 2004 | 174 | 0.050 |
Why?
|
RNA, Viral | 1 | 2022 | 52 | 0.050 |
Why?
|
Telecommunications | 1 | 2001 | 7 | 0.050 |
Why?
|
Behavior | 1 | 2001 | 31 | 0.050 |
Why?
|
Adolescent Development | 1 | 2020 | 2 | 0.050 |
Why?
|
Problem Solving | 1 | 2001 | 28 | 0.050 |
Why?
|
Employer Health Costs | 1 | 2000 | 1 | 0.050 |
Why?
|
Psychiatric Department, Hospital | 1 | 2000 | 2 | 0.050 |
Why?
|
Health Maintenance Organizations | 1 | 2000 | 14 | 0.050 |
Why?
|
Emotions | 1 | 2021 | 56 | 0.050 |
Why?
|
Patient Admission | 1 | 2001 | 62 | 0.050 |
Why?
|
Antisocial Personality Disorder | 1 | 2020 | 2 | 0.050 |
Why?
|
Sex Distribution | 2 | 2015 | 201 | 0.050 |
Why?
|
Outpatients | 1 | 2000 | 58 | 0.050 |
Why?
|
Interleukin-6 | 3 | 2006 | 248 | 0.050 |
Why?
|
Disease Progression | 2 | 2019 | 618 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2022 | 188 | 0.050 |
Why?
|
Demography | 3 | 2009 | 109 | 0.050 |
Why?
|
Dizziness | 1 | 2020 | 12 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 48 | 0.040 |
Why?
|
Mental Recall | 1 | 2020 | 51 | 0.040 |
Why?
|
Maryland | 1 | 2019 | 28 | 0.040 |
Why?
|
Memory | 2 | 1998 | 191 | 0.040 |
Why?
|
Inpatients | 1 | 2000 | 78 | 0.040 |
Why?
|
Computer Simulation | 1 | 2001 | 220 | 0.040 |
Why?
|
Disabled Persons | 1 | 2000 | 103 | 0.040 |
Why?
|
Dyspnea | 1 | 2020 | 34 | 0.040 |
Why?
|
Serologic Tests | 1 | 2019 | 11 | 0.040 |
Why?
|
Social Perception | 1 | 2019 | 25 | 0.040 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2000 | 53 | 0.040 |
Why?
|
Bisexuality | 1 | 2019 | 17 | 0.040 |
Why?
|
Iontophoresis | 1 | 1999 | 6 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2000 | 140 | 0.040 |
Why?
|
Achilles Tendon | 1 | 1999 | 22 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2015 | 911 | 0.040 |
Why?
|
Health Status Indicators | 1 | 1999 | 74 | 0.040 |
Why?
|
Dexamethasone | 1 | 1999 | 44 | 0.040 |
Why?
|
beta Carotene | 1 | 1998 | 6 | 0.040 |
Why?
|
Vitamin E | 1 | 1998 | 23 | 0.040 |
Why?
|
Ascorbic Acid | 1 | 1998 | 23 | 0.040 |
Why?
|
Adolescent, Hospitalized | 1 | 1998 | 2 | 0.040 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2018 | 27 | 0.040 |
Why?
|
Placebos | 1 | 1998 | 66 | 0.040 |
Why?
|
Telephone | 1 | 2019 | 59 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2014 | 696 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 1999 | 102 | 0.040 |
Why?
|
Diabetic Retinopathy | 1 | 1998 | 64 | 0.040 |
Why?
|
Social Class | 1 | 2018 | 89 | 0.040 |
Why?
|
Health Behavior | 1 | 2019 | 229 | 0.040 |
Why?
|
Antioxidants | 1 | 1998 | 114 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2019 | 245 | 0.040 |
Why?
|
Phenotype | 1 | 2019 | 656 | 0.040 |
Why?
|
Prognosis | 2 | 2018 | 1523 | 0.040 |
Why?
|
Feeding Behavior | 1 | 2019 | 162 | 0.040 |
Why?
|
Sneezing | 2 | 2007 | 6 | 0.040 |
Why?
|
Dietary Supplements | 1 | 1998 | 184 | 0.040 |
Why?
|
Continental Population Groups | 1 | 2018 | 239 | 0.040 |
Why?
|
Cognition | 1 | 2001 | 551 | 0.040 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2007 | 27 | 0.030 |
Why?
|
Dementia | 1 | 1998 | 256 | 0.030 |
Why?
|
Macaca mulatta | 2 | 2007 | 332 | 0.030 |
Why?
|
Exercise | 1 | 2000 | 655 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2004 | 877 | 0.030 |
Why?
|
Public Policy | 1 | 2015 | 34 | 0.030 |
Why?
|
Age Distribution | 1 | 2015 | 210 | 0.030 |
Why?
|
Emigration and Immigration | 1 | 2015 | 32 | 0.030 |
Why?
|
State Government | 1 | 2014 | 32 | 0.030 |
Why?
|
Southeastern United States | 1 | 2014 | 81 | 0.030 |
Why?
|
Prenatal Care | 1 | 2015 | 52 | 0.030 |
Why?
|
Tobacco Industry | 1 | 2014 | 17 | 0.030 |
Why?
|
Personality | 1 | 2014 | 16 | 0.030 |
Why?
|
Acculturation | 1 | 2014 | 17 | 0.030 |
Why?
|
Tablets | 1 | 2013 | 10 | 0.030 |
Why?
|
Progesterone Congeners | 2 | 2004 | 15 | 0.030 |
Why?
|
Linear Models | 2 | 2006 | 454 | 0.030 |
Why?
|
Administration, Oral | 1 | 2013 | 185 | 0.030 |
Why?
|
Attitude to Health | 1 | 2014 | 167 | 0.030 |
Why?
|
Patient Discharge | 2 | 2006 | 183 | 0.030 |
Why?
|
Incidence | 1 | 2015 | 1207 | 0.020 |
Why?
|
Affect | 2 | 2001 | 69 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2013 | 3514 | 0.020 |
Why?
|
Geriatric Assessment | 2 | 2001 | 395 | 0.020 |
Why?
|
Communicable Disease Control | 1 | 2007 | 15 | 0.020 |
Why?
|
Particulate Matter | 1 | 2007 | 31 | 0.020 |
Why?
|
Haloperidol | 1 | 2007 | 5 | 0.020 |
Why?
|
Quinpirole | 1 | 2007 | 15 | 0.020 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2006 | 5 | 0.020 |
Why?
|
Intention | 1 | 2006 | 28 | 0.020 |
Why?
|
Empathy | 1 | 2006 | 19 | 0.020 |
Why?
|
Schools, Medical | 1 | 2006 | 46 | 0.020 |
Why?
|
Receptors, Dopamine D2 | 1 | 2007 | 79 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2005 | 41 | 0.020 |
Why?
|
Atmosphere Exposure Chambers | 1 | 2005 | 3 | 0.020 |
Why?
|
Psychological Tests | 1 | 2005 | 35 | 0.020 |
Why?
|
Reference Values | 1 | 2005 | 255 | 0.020 |
Why?
|
Physical Fitness | 1 | 2006 | 127 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2005 | 89 | 0.020 |
Why?
|
Curriculum | 1 | 2006 | 210 | 0.020 |
Why?
|
Coagulase | 1 | 2004 | 3 | 0.020 |
Why?
|
Ribotyping | 1 | 2004 | 3 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 2004 | 18 | 0.020 |
Why?
|
Methicillin Resistance | 1 | 2004 | 14 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2004 | 42 | 0.010 |
Why?
|
Hospitals, Psychiatric | 1 | 2003 | 2 | 0.010 |
Why?
|
Risk | 1 | 2004 | 325 | 0.010 |
Why?
|
Skin | 1 | 2005 | 217 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2007 | 1040 | 0.010 |
Why?
|
Body Mass Index | 1 | 2006 | 921 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 279 | 0.010 |
Why?
|
Survival Analysis | 1 | 2003 | 491 | 0.010 |
Why?
|
Walking | 1 | 2002 | 204 | 0.010 |
Why?
|
Arteriosclerosis | 1 | 2000 | 122 | 0.010 |
Why?
|
Arthritis | 1 | 2000 | 40 | 0.010 |
Why?
|
Rats | 1 | 2004 | 1675 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 1999 | 43 | 0.010 |
Why?
|
Neurobehavioral Manifestations | 1 | 1998 | 1 | 0.010 |
Why?
|
Colorado | 1 | 1998 | 41 | 0.010 |
Why?
|
Rabbits | 1 | 1999 | 199 | 0.010 |
Why?
|
Vasomotor System | 1 | 1998 | 21 | 0.010 |
Why?
|
California | 1 | 1998 | 64 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 1998 | 102 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2000 | 600 | 0.010 |
Why?
|
Weight Gain | 1 | 1998 | 114 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 1998 | 301 | 0.010 |
Why?
|
Recurrence | 1 | 1998 | 266 | 0.010 |
Why?
|
Patient Selection | 1 | 1999 | 289 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2006 | 1133 | 0.010 |
Why?
|
Women's Health | 1 | 1998 | 235 | 0.010 |
Why?
|
Weight Loss | 1 | 1999 | 454 | 0.010 |
Why?
|
Risk Assessment | 1 | 1999 | 1447 | 0.010 |
Why?
|
Hypertension | 1 | 2000 | 972 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2001 | 3358 | 0.010 |
Why?
|